Citius Oncology Inc. (CTOR)
NASDAQ: CTOR
· Real-Time Price · USD
1.63
0.02 (1.24%)
At close: Aug 21, 2025, 3:59 PM
1.73
6.13%
After-hours: Aug 21, 2025, 06:14 PM EDT
Citius Oncology Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Apr 30, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -25.48M | -20.92M | -13.72M | -7.57M | -1.32M | -934.02K | -665.59K | -421.45K | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Income | n/a | 636.42K | 1.39M | 2.67M | 3.25M | 2.62M | 1.86M | 579.4K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -25.64M | -20.28M | -12.32M | -10.51M | -3.68M | -3.94M | -4.43M | 157.94K | n/a | n/a | n/a | n/a | -9.39K | -9.39K |
Net Income | -26.58M | -25.98M | -17.76M | -15.82M | -8.85M | -4.08M | -4.57M | 157.94K | -8.57K | -10.87K | -10.87K | -10.87K | -11.69K | -9.39K |
Selling & General & Admin | 18.84M | 18.33M | 17.34M | 15.65M | 14.17M | 10.67M | 7.33M | 3.89M | n/a | n/a | n/a | n/a | n/a | n/a |
Research & Development | 6.64M | 6.83M | 5.04M | 4.93M | 4.78M | 3.65M | 2.3M | 1.15M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | n/a | n/a | n/a | -4.62M | -4.62M | -4.62M | -4.62M | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 25.48M | 25.16M | 22.38M | 20.57M | 14.33M | 9.7M | 5M | 421.45K | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Expense | 160.75K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 25.48M | 25.16M | 22.38M | 20.57M | 14.33M | 9.7M | 5M | 421.45K | n/a | n/a | n/a | n/a | n/a | n/a |
Income Tax Expense | 799.53K | 540.06K | 280.66K | 21.15K | 19.52K | 17.48K | 15.57K | 12.7K | 16.08K | 15.65K | 12.72K | 10.87K | 2.3K | n/a |
Shares Outstanding (Basic) | 71.55M | 71.55M | 71.55M | 71.55M | 66.53M | 66.53M | 89.41M | 89.42M | 90.16M | 90.16M | 90.16M | 90.16M | 81.4M | 66.42M |
Shares Outstanding (Diluted) | 71.55M | 71.55M | 71.55M | 71.55M | 66.53M | 66.53M | 89.41M | 89.42M | 90.16M | 90.16M | 90.16M | 90.16M | 81.4M | 66.42M |
EPS (Basic) | -0.59 | -0.48 | -0.29 | -0.08 | 0.25 | 0.28 | 0.27 | 0.20 | 0.18 | 0.11 | 0.04 | -0.00 | -0.00 | -0.00 |
EPS (Diluted) | -0.59 | -0.48 | -0.29 | -0.08 | 0.25 | 0.28 | 0.27 | 0.20 | 0.18 | 0.11 | 0.04 | -0.00 | -0.00 | -0.00 |
EBITDA | -18.81M | -13.61M | -5.65M | 1.78M | 1.93M | 1.68M | 1.19M | 157.94K | n/a | n/a | n/a | n/a | -9.39K | -9.39K |
EBIT | -25.48M | -20.28M | -12.32M | -4.89M | 1.93M | 1.68M | 1.19M | 157.94K | n/a | n/a | n/a | n/a | -9.39K | -9.39K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |